We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

European Nonprofit to Focus on Personalized Medicine and Diagnostics

By LabMedica International staff writers
Posted on 09 Nov 2009
A nonprofit launched in Europe will focus on promoting and harmonizing personalized medicine and implementing "high value" diagnostics across the continent.

The European Personalized Medicine Diagnostics Association (EPEMED; Nantes, France), a membership association formed in August 2009 as a not-for-profit organization, will provide a platform for harmonization in the development and implementation of value-based diagnostics across Europe, to make personalized medicine a reality. Personalized Medicine refers to the use of a person's clinical, genetic, genomic, and environmental information to select more precisely and accurately treatment for each individual patient. Its aims are to improve care and lower costs.

The central goals of EPEMED are to move personalized medicine forward throughout Europe through targeted education, idea sharing, and business models. The group plans to create joint programs with other international personalized medicine organizations, and to offer opinions on policies related to the field.

EPEMED appointed experts in the field of personalized medicine and molecular diagnostics as its founding board of directors. They include executives from Ipsogen (Marseilles, France), Genzyme Genetics (Cambridge, MA, USA), the Personalized Medicine Coalition (Washington, DC, USA), Theranostics (Rockville, MD, USA), and Novartis Molecular Diagnostics (East Hanover, NJ, USA), as well as from academic and institutional researchers, other businesses, and patient advocacy groups.

"The next few years will see deep changes in medical care due to the development of breakthrough innovations in the field of molecular diagnostics that will help clinicians in better treating their patients," Alain Huriez, founder and chairman of EPEMED, said in a statement. "It is our responsibility to make sure that these innovations will be made available to European patients and as a result, to make Europe an attractive place for innovations, financial and industrial investments in the area of personalized medicine diagnostics."

Related Links:

European Personalised Medicine Diagnostics Association
Ipsogen
Genzyme Genetics
Personalized Medicine Coalition
Theranostics
Novartis Molecular Diagnostics


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Automated Blood Typing System
IH-500 NEXT
New
PSA Test
Human Semen Rapid Test
New
FLU/RSV Test
Humasis FLU/RSV Combo

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests